Skip to Content

Steglujan Approval History

  • FDA approved: Yes (First approved December 19th, 2017)
  • Brand name: Steglujan
  • Generic name: ertugliflozin and sitagliptin
  • Dosage form: Tablets
  • Company: Merck & Co., Inc.
  • Treatment for: Diabetes, Type 2

Steglujan (ertugliflozin and sitagliptin) is a sodium glucose co-transporter 2 (SGLT2) inhibitor, and dipeptidyl peptidase-4 (DPP-4) inhibitor combination used to improve glycemic control in adults with type 2 diabetes.

Development History and FDA Approval Process for Steglujan

Dec 22, 2017Approval FDA Approves Steglujan (ertugliflozin and sitagliptin) for Type 2 Diabetes

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.